New Delhi, Aug. 5 -- The recent decision by the United States to impose a 25% tariff on certain Chinese-made pharmaceutical ingredients could indirectly impact Indian pharmaceutical companies, according to industry analysts.

Even though Indian companies largely depend on Chinese imports for active pharmaceutical ingredients (APIs), the ability to pass on higher costs to customers may not fully shield them from margin pressures.

Indian pharma firms source over 60% of their bulk drug needs from China. While the new US tariff does not directly target Indian exports, it may disrupt the global supply chain and increase input costs.

Companies might try to transfer these rising expenses to customers, but analysts say the margin impact could s...